BIOMARKER TESTING IN NSCLC: A LANDSCAPE ASSESSMENT OF ADMINISTRATIVE DATA
Author(s)
Pamala A. Pawloski, PharmD1, Scott Matthew Myers, MBA2, Cate Lockhart, MS, PharmD, PhD1.
1Academy of Managed Care Pharmacy (AMCP) Research Institute, Alexandria, VA, USA, 2PearlDiver Inc., Colorado Springs, CO, USA.
1Academy of Managed Care Pharmacy (AMCP) Research Institute, Alexandria, VA, USA, 2PearlDiver Inc., Colorado Springs, CO, USA.
OBJECTIVES: Oncology precision medicine (PM) aims to deliver high-quality, evidence-based care. Despite recommendations for broad panel biomarker testing for all newly diagnosed non-small cell lung cancer (NSCLC), limited studies report sub-optimal biomarker testing rates. We describe the current biomarker testing landscape among patients diagnosed with NSCLC and quantify biomarker testing and treatment utilization.
METHODS: We assessed biomarker testing and treatment receipt, with and without biomarker testing, based on patient demographics, comorbid conditions, and payer type among adults with a lung cancer diagnosis in a large, US, multi-payer claims database of 174 million lives from 2010-2023. We assessed patients in two cohorts, 2010-2018 (Early) and 2019-2023 (Late) to ascertain testing rates relative to recommended changes for comprehensive testing.
RESULTS: Of 1,148,032 lung cancer diagnoses, 575,382 (50.1%) received biomarker testing overall; although testing increased over time, 45.6% (Early) and 58.0% (Late) cohorts and broad panel testing was 1.95% and 4.2%, respectively. Biomarker testing increased from the Early to Late cohorts among males (44.2%-57.2%; p<0.05) and females (46.5%-58.6%; p<0.05), respectively. Testing rates increased significantly (p<0.05) between the Early and Late cohorts across age groups with an average increase of 8.1% (3.3%-14.7%). Biomarker testing for those with commercial insurance increased from 53.5% (Early) to 61.6% (Late), p<0.05, 34.3%-53.4% (p<0.05) for Medicare, and 43.7%-54.3% (p<0.05) for Medicaid, respectively. Receipt of targeted therapy among the biomarker tested was 29.2% (Early) and 42.9% (Late). Overall, the mean Charlson comorbidity index (CCI) and the risk analysis index (RAI) frailty score were both greatest among those biomarker tested who received targeted therapy.
CONCLUSIONS: Among patients with a diagnosis of lung cancer, biomarker testing remains low but is increasing over time across sex, age, and health plan coverage, and the receipt of targeted therapy has increased but is also identified and increasing among those without claims for biomarker testing.
METHODS: We assessed biomarker testing and treatment receipt, with and without biomarker testing, based on patient demographics, comorbid conditions, and payer type among adults with a lung cancer diagnosis in a large, US, multi-payer claims database of 174 million lives from 2010-2023. We assessed patients in two cohorts, 2010-2018 (Early) and 2019-2023 (Late) to ascertain testing rates relative to recommended changes for comprehensive testing.
RESULTS: Of 1,148,032 lung cancer diagnoses, 575,382 (50.1%) received biomarker testing overall; although testing increased over time, 45.6% (Early) and 58.0% (Late) cohorts and broad panel testing was 1.95% and 4.2%, respectively. Biomarker testing increased from the Early to Late cohorts among males (44.2%-57.2%; p<0.05) and females (46.5%-58.6%; p<0.05), respectively. Testing rates increased significantly (p<0.05) between the Early and Late cohorts across age groups with an average increase of 8.1% (3.3%-14.7%). Biomarker testing for those with commercial insurance increased from 53.5% (Early) to 61.6% (Late), p<0.05, 34.3%-53.4% (p<0.05) for Medicare, and 43.7%-54.3% (p<0.05) for Medicaid, respectively. Receipt of targeted therapy among the biomarker tested was 29.2% (Early) and 42.9% (Late). Overall, the mean Charlson comorbidity index (CCI) and the risk analysis index (RAI) frailty score were both greatest among those biomarker tested who received targeted therapy.
CONCLUSIONS: Among patients with a diagnosis of lung cancer, biomarker testing remains low but is increasing over time across sex, age, and health plan coverage, and the receipt of targeted therapy has increased but is also identified and increasing among those without claims for biomarker testing.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
RWD132
Topic
Health Service Delivery & Process of Care, Real World Data & Information Systems
Topic Subcategory
Health & Insurance Records Systems
Disease
Oncology